⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Empiri Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Empiri Inc.
↗Houston, USA
Empiri Inc. is a biotechnology company based in Houston, Texas, specializing in functional precision oncology. The company has developed a proprietary 3D tissue culture platform known as 'E-Slice,' which preserves the tumor microenvironment, including immune infiltrates, to provide functional drug response data from intact human tumor slices within 7–12 days.
Empiri operates as a translational oncology CRO, providing services to biopharma clients and clinical researchers to optimize trial design, de-risk clinical decisions, and improve treatment precision. The company is a 10x Genomics Certified Service Provider and collaborates with major medical institutions, including MD Anderson and Houston Methodist Research Institute.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Seed
Investors:JLABS
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service/Platform Provider)
Modalities:Precision Diagnostics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:MD Anderson Cancer Center (Clinical collaboration), Houston Methodist Research Institute (Clinical collaboration), 10x Genomics (Certified Service Provider)
COMPETITION
Position:Emerging
Competitors:Nanovery, Scholar Rock, SamanTree Medical
LEADERSHIP
Key Executives:
Kyuson Yun - Founder
Linus Ho - Medical Director
Scientific Founders:Kyuson Yun
LINKS
Website:empiricancer.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Empiri Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.